Revisión del uso de los medicamentos biosimilares vs. biológicos: implicaciones para la salud en Colombia.

dc.contributorGonzalez-Rodriguez, Javier-Leonardo
dc.creatorGuzmán Ramírez, Gina Melissa
dc.creatorRamírez Campos, Martin
dc.creatorDelgado Montero, Camila Andrea
dc.date.accessioned2016-07-05T19:46:50Z
dc.date.available2016-07-05T19:46:50Z
dc.date.created2016-07-05T19:46:50Z
dc.date.issued2016
dc.identifierhttp://repository.urosario.edu.co/handle/10336/12196
dc.identifierhttps://doi.org/10.48713/10336_12196
dc.description.abstractThis paper aims to describe the health implications with the use of biosimilars compared with biological drugs in Colombia. Also, described the regulatory context about the use of biosimilars, recommendations and guidelines on safety and effectiveness of using biosimilar and biological medicines, based on their biomolecular differences. For this, an electronic document review and manual literature databases, magazines and books limited MeSH terms was developed. The selection of items included full papers published in indexed journals from last 10 years, in Spanish and English; the information collected was organized for the construction of this document. In conclusion, we found that many biological drugs patents have expired or are close to expiring and several biosimilars are being developed and marketed even in countries without strict regulations. Biosimilars can never be equal to the original by their molecular complexity, so we must integrate pharmacovigilance systems to improve traceability and identify their origin while distinguishable nonproprietary names are set. Current evidence suggests that regulation of biosimilar medicines should be evaluated and harmonized worldwide.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherMaestría en Administración en Salud
dc.publisherFacultad de administración
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto completo)
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.sourceKay J, Feagan BG, Guirguis MS, Keystone EC, Klein A V., Lubiniecki AS, et al. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals. 2012;40(6):517–27.
dc.sourceCasadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, et al. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther [Internet]. Informa UK, Ltd.; 2013;13(7):1039–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23527621
dc.sourceAlerany C, Armellini A, Bosó V, Calvo G, Cruz E, Diego L et al. Libro Blanco de los medicamentos biosimilares en España: Calidad Sostenible. Fundación . Casal FG, editor. España; 2014.
dc.sourceTaylor P, Abraham I, Sun D, Bagalagel A, Altyar A, Mohammed A, et al. Biosimilars in 3D Biosimilars in 3D Definition , development and differentiation © 2013 Landes Bioscience . Do not distribute. 2013;(April 2015):37–41.
dc.sourceMysler E, Scheinberg M. Biosimilars in rheumatology: A view from Latin America. Clin Rheumatol. 2012;31(9):1279–80.
dc.sourceFazzolare DA, Brougher JT. What the patent dance of the biosimilars act means for biosimilars. J Commer Biotechnol. 2014;20(4):31–6.
dc.sourceCDER/CBER, FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guid Ind. 2015;(February).
dc.sourceMazur M, Olek-hrab K, Karczewski J, Teresiak-mikołajczak E, Adamski Z. Biosimilars in dermatology. 2015;384–7.
dc.sourceOwens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations--a cause for concern? Diabetes Technol Ther [Internet]. 2012;14(11):989–96. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3698679&tool=pmcentrez&rendertype=abstract
dc.sourceMiller BHI. Still Awaiting the “Biosimilars” Revolution. 2015;22–6.
dc.sourceMellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19(3):411–9.
dc.sourceUribe CVC. Triunfalismo del decreto de los biosimilares. Salud Uninorte. 2014;30(3):7–9.
dc.sourcePineda C, Caballero-Uribe C V., de Oliveira MG, Lipszyc PS, Lopez JJ, Mataos Moreira MM, et al. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol. 2015;34(4):635–40.
dc.sourceINVIMA IN de V de M y A. Glosario de Términos - INVIMA [Internet]. 03 Enero 2012. 2016 [cited 2015 Oct 14]. Available from: https://www.invima.gov.co/index.php?option=com_content&view=article&id=770&Itemid=242
dc.sourceMinisterio de Salud y Protección Social. DECRETO 1782 DEL 18 DE SEPTIEMBRE DE 2014 [Internet]. 19 Septiembre 2014. [cited 2015 Oct 14]. Available from: https://www.invima.gov.co/index.php?option=com_content&view=article&id=3597:decreto-1782-del-18-de-septiembre-de-2014&catid=144:decretos-medicamentos-&Itemid=200).
dc.sourceSimoens S, Verbeken G, Huys I. Biosimilars and market access: A question of comparability and costs? Target Oncol. 2012;7(4):227–31.
dc.sourceStrand V, Cronstein B. Biosimilars: How similar? Intern Med J. 2014;44(3):218–23.
dc.sourceCrommelin DJA, Shah VP, Klebovich I, McNeil SE, Weinstein V, Fl??hmann B, et al. The similarity question for biologicals and non-biological complex drugs. Eur J Pharm Sci [Internet]. Elsevier B.V.; 2015;76:10–7. Available from: http://dx.doi.org/10.1016/j.ejps.2015.04.010
dc.sourceBocquet F, Paubel P, Fusier I, Cordonnier AL, Sin??gre M, Le Pen C. Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience. Appl Health Econ Health Policy. 2015;13(1):47–59.
dc.sourceMartos Rosa A, Martínez de la Plata JE, Morales Molina JA, Fayet Pérez A, Acosta Robles PJ. Biosimilares, el camino ha comenzado. Farm Hosp órgano Of expresión científica la Soc Española Farm Hosp [Internet]. 2015;39(2):114–7. Available from: http://dialnet.unirioja.es/servlet/articulo?codigo=5027043&info=resumen&idioma=ENG
dc.sourceGascon P. Presently available biosimilars in hematology-oncology - Part II: G-CSF. Oncologie. 2011;13(5):213–7.
dc.sourceCalvo B, Zúñiga L. Medicamentos Biotecnológicos: Requisitos Exigidos para el Desarrollo y Aprobación de Biosimilares. Inf Tecnol. 2010;21(6):125–32.
dc.sourceKramer I. Pharmacy anfd pharmacology of biosimilars. J endocrinol Invest. 2008;31(Table 1):479–86.
dc.sourceLucio SD, Pharm D. Biosimilars : Primer for the Health-System Pharmacist. Am J Heal Pharm. 2014;70(22):2004–17.
dc.sourceCastro-ayarza JR, González C, Velásquez-lopera MM, Londoño M, Cárdenas ZB, Castro-ayarza JR. Actualización en biosimilares : una reflexión sobre la reglamentación en Colombia de los medicamentos biológicos y biosimilares. Rev Asoc Colomb Dermatol. 2015;1:23–9.
dc.sourceGrampp G, Felix T. Pharmacovigilance Considerations for Biosimilars in the USA. BioDrugs [Internet]. Springer International Publishing; 2015;29(5):309–21. Available from: "http://dx.doi.org/10.1007/s40259-015-0137-2
dc.sourceRamanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28(4):363–72.
dc.sourceLocatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant. 2006;21(SUPPL. 5):13–6.
dc.sourceBerkowitz S, Engen J, Mazzeo J, Jones G. Analytical Tools for Characterizing biopharmaceuticals and the Implications for Biosimilars. Nat Rev Drug Discov. 2013;11(October 2010):527–40.
dc.sourceLetelier OV, Vodnizza SI. Biosimilares : ¿ Qué tan similares ? 2014;30(2):52–8.
dc.sourceMachado-Alba JE, Ruiz AF, Machado-Duque ME. Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Rev Panam Salud Publica. 2014;36(6):396–401.
dc.sourcePoh J, Tam KT. Registration of similar biological products - Singapore’s approach. Biologicals [Internet]. Elsevier Ltd; 2011;39(5):343–5. Available from: http://dx.doi.org/10.1016/j.biologicals.2011.06.011
dc.sourceVermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, et al. Traceability of biologicals: present challenges in pharmacovigilance. Expert Opin Drug Saf [Internet]. 2014;14(1):63–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25369769
dc.sourceÁngel M, Hernández A, Luis J, Ángel M, Ruiz C, Ángel M, et al. Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares. 2015;11(5):269–78.
dc.sourceTothfalusi L, Endrenyi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Heal Econ. 2014;15(SUPPL. 1):5–12.
dc.sourceGatica Rossi HA. Bioequivalencia, Biosimilares, Biológicos Subsecuentes, Medicamentos Intercambia- bles o Sustituibles, ¿Son lo Mismo? 2014;30(3):119–21.
dc.sourcevan de Vooren K, Curto A, Garattini L. Biosimilar Versus Generic Drugs: Same But Different? Appl Health Econ Health Policy. 2015;13(2):125–7.
dc.sourceLi E, Ramanan S, Green L. Pharmacist Substitution of Biological Products: Issues and Considerations. J Manag Care Spec Pharm. 2015;21(7):532–9.
dc.sourceBennett CL, Chen B, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol [Internet]. Elsevier Ltd; 2014;15(13):e594–605. Available from: http://dx.doi.org/10.1016/S1470-2045(14)70365-1
dc.sourceEspinosa Morales R, Díaz Borjón A, Barile Fabris LA, Esquivel Valerio JA, Medrano Ramírez G, Arce Salinas CA, et al. Biosimilar Drugs in Mexico: Position of the Mexican College of Rheumatology, 2012. Reumatol Clínica (English Ed [Internet]. 2013;9(2):113–6. Available from: http://www.sciencedirect.com/science/article/pii/S2173574313000269
dc.sourceCastañeda-Hernandez G, Szekanecz Z, Mysler E, Azevedo VF, Guzman R, Gutierrez M, et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies. Jt Bone Spine. 2014;81(6):471–7.
dc.sourceManrique López SM, Jimenez Barbosa WG. Mercado de Medicamentos Biotecnológicos en el Sistema General de Seguridad Social en Salud. Cienc Tecnol para la salud Vis y Ocul [Internet]. 2012;10 (2):59–78. Available from: http://aprendeenlinea.udea.edu.co/lms/moodle/file.php/319/Lecturas_de_interes_en_Financiacion_del_SGSSS/Sostenibilidad_Financiera_del_SGSSS_Fernando_Ruiz_.pdf
dc.sourceMinisterio de Salud y Proteccion social de la Republica de Colombia. Sobre medicamentos biotecnológicos. 2014;1–5.
dc.sourceBaji P, Pentek M, Czirjak L, Szekanecz Z, Nagy G, Gulacsi L, et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: A mixed treatment comparison. Eur J Heal Econ. 2014;15(SUPPL. 1).
dc.sourceGascon P. The evolving role of biosimilars in haematology-oncology: a practical perspective. Ther Adv Hematol [Internet]. 2015;6(6):267–81. Available from: http://tah.sagepub.com/lookup/doi/10.1177/2040620715613715
dc.sourceGottlieb S. Biosimilars: Policy, clinical, and regulatory considerations. Am J Heal Pharm. 2008;65(14 SUPPL. 6):2–9.
dc.sourceS IS, S LQ. Intercambiabilidad de medicamentos de origen biológico (biofármacos): Consideraciones acerca de la aprobación de formulaciones biosimilares (biogenéricos) en Chila. Rev Med Chile. 2006;134:1583–8.
dc.sourceStewart A, Aubrey P, Belsey J. Addressing the health technology assessment of biosimilar pharmaceuticals. Curr Med Res Opin. 2010;26(9):2119–26.
dc.sourcePaul J Declerck SS. A European Perspective on the Market Accessibility of biosimilars. Biosimilars. 2012;2:33–40.
dc.sourceDeVries JH, Gough SCL, Kiljanski J, Heinemann L. Biosimilar insulins: a European perspective. Diabetes Obes Metab [Internet]. 2015;17(5):445–51. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4403967&tool=pmcentrez&rendertype=abstract
dc.sourceSchellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus [Internet]. 2009;2(Suppl_1):i27–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19461855http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2638545
dc.sourceLai Z, Noce A La. Key design considerations on comparative clinical efficacy studies for biosimilars : adalimumab as an example. 2016;1–13.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectBiosimilares
dc.subjectbiológicos
dc.subjectfarmacovigilancia
dc.subjecttrazabilidad
dc.subjectinmunogenicidad
dc.titleRevisión del uso de los medicamentos biosimilares vs. biológicos: implicaciones para la salud en Colombia.
dc.typemasterThesis


Este ítem pertenece a la siguiente institución